DK200101258A - Stabiliseret oral farmaceutisk sammensætning indeholdende iodid og iodat samt fremgangsmåde til fremstilling heraf - Google Patents

Stabiliseret oral farmaceutisk sammensætning indeholdende iodid og iodat samt fremgangsmåde til fremstilling heraf Download PDF

Info

Publication number
DK200101258A
DK200101258A DK200101258A DKPA200101258A DK200101258A DK 200101258 A DK200101258 A DK 200101258A DK 200101258 A DK200101258 A DK 200101258A DK PA200101258 A DKPA200101258 A DK PA200101258A DK 200101258 A DK200101258 A DK 200101258A
Authority
DK
Denmark
Prior art keywords
iodate
iodide
pharmaceutical composition
sodium
preparation
Prior art date
Application number
DK200101258A
Other languages
English (en)
Inventor
Duan Yongjun
Dinehart Kirk
Kessler Jack
Hickey John
Original Assignee
Symbollon Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Symbollon Corp filed Critical Symbollon Corp
Publication of DK200101258A publication Critical patent/DK200101258A/da
Application granted granted Critical
Publication of DK176595B1 publication Critical patent/DK176595B1/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/40—Peroxides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/18—Iodine; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/14—Drugs for genital or sexual disorders; Contraceptives for lactation disorders, e.g. galactorrhoea
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1611—Inorganic compounds

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Inorganic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Reproductive Health (AREA)
  • Diabetes (AREA)
  • Pregnancy & Childbirth (AREA)
  • Gynecology & Obstetrics (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Description

PATENTKRAV 1. Stabiliseret fast oral farmaceutisk sammensætning omfattende jodid og jodat i kombination med mindst en anden farmaceutisk excipiens omfattende mindst et pH-regu-Ieringsmiddel på en sådan måde, at sammensætningens effektive pH-værdi er mellem 7,0 og 12,0. 2. Sammensætning ifølge krav 1, hvori jodidkilden er valgt fra gruppen bestående af cal-ciumjodid, natriumjodid, kaliumjodid, magnesiumjodid, zinkjodid, cuprijodid og mangan-jodid. 3. Sammensætning ifølge krav 1, hvori jodatkilden er valgt fra gruppen bestående af cal-ciumjodat, natriumjodat, kaliumjodat, magnesiumjodat, zinkjodat, cuprijodat ogmanganjo-dat. 4. Sammensætning ifølge krav 1, hvori pH-reguleringsmidlet er valgt fra klassen bestående af natriumcarbonat, calciumcarbonat, kaliumcarbonat, magnesiumcarbonat, natriumhydroxid, bentonit (Al203-4Si02-H20), dibasisk calciumphosphatdihydrat, magnesiumoxid, magnesiumtrisilikat, natriumbicarbonat, dibasisk natriumphosphat, tribasisknatriumphos-phat, dibasisk kaliumphosphat og tribasisk kaliumphosphat. 5. Sammensætning ifølge krav 1, hvori de farmaceutiske excipienser er valgt fra klassen bestående af natriumalginat, alginsyre, dicalciumphosphater, tricalciumphosphat, mikro-cellulose, citronsyre, fructose, magnesiumstearat, a-cyclodextrin, β-cyclodextrin, γ-cyclo-dextrin, povidon, hydroxypropylmethylcellulose, hydroxypropylmethylcellulosephthalat, dinatriumphosphater, natriumstearat, sorbitol, stivelse, saccharose, natriumacetat, natrium-carboxymethylcellulose, ethylvanilin, mannitol, natriumchlorid, calciumsulfat, maltodex-trin, dextrose, dextrin, dextrater, myvatex-TL og saccharin. 6. Fremgangsmåde til fremstilling af en fast oral farmaceutisk sammensætning med et fugtigjiedsindhold på ikke mere end ca. 2% indeholdende jodid og jodat i kombination med mindst en farmaceutisk acceptabel excipiens omfattende mindst et pH-regulerings-middel, således at sammensætningens effektive pH-værdi er mellem 7,0 og 12,0, hvilken fremgangsmåde bevirker fordeling af jodat og jodid i en fast dosisform på en i alt væsentligt homogen måde og omfatter enten (a) granuleringen af en opløsning indeholdende j odat og/eller jodid på farmaceutisk acceptable excipienser eller (b) "slugging" af jodat og jodid i en fast matrix. 7. Fremgangsmåde ifølge krav 6, hvori jodidkilden er valgt fra gruppen bestående af cal-ciumjodid, natriumjodid, kaliumjodid, magnesiumjodid, zinkjodid, cuprijodid og mangan-jodid. 8. Fremgangsmåde ifølge krav 6, hvori jodatkilden er valgt fra gruppen bestående af cal-ciumjodat, natriumjodat, kaliumjodat, magnesiumjodat, zinkjodat, cuprijodat ogmanganjo-dat. 9. Fremgangsmåde ifølge krav 6, hvori pH-reguleringsmidlet er valgt fra gruppen bestående af natriumcarbonat, calciumcarbonat, kaliumcarbonat, magnesiumcarbonat, natriumhydroxid, bentonit(AI203-4Si02-H20), dibasisk calciumphosphatdihydrat, magnesiumoxid, magnesiumtrisilikat, natriumbicarbonat, dibasisk natriumphosphat, tribasisk natriumphos-phat, dibasisk kaliumphosphat og tribasisk kaliumphosphat. 10. Fremgangsmåde ifølge krav 6, hvor de farmaceutiske excipienser er valgt fra gruppen bestående af natriumalginat, alginsyre, dicalciumphosphater, tricalciumphosphat, mikro-cellulose, citronsyre, fructose, magnesiumstearat, a-cyclodextrin, β-cyclodextrin, γ-cyclo-dextrin, povidon, hydroxypropylmethylcellulose, hydroxypropylmethylcellulosephthalat, dinatriumphosphater, natriumstearat, sorbitol, stivelse, saccharose, natriumacetat, natrium-carboxymethylcellulose, ethylvanilin, mannitol, natriumchlorid, calciumsulfat, maltodex-trin, dextrose, dextrin, dextrater, myvatex-TL og saccharin. 11. Fremgangsmåde ifølge krav 6, hvori den faste, farmaceutiske sammensætning fremstilles ved granulering af jodid og jodat på farmaceutiske excipienser. 12. Fremgangsmåde ifølge krav 6, hvori jodid og jodat opløses i en granuleringsopløsning, som har en pH-værdi på mere end 7,0 og mere foretrukket mere end 8,0, og granuleringsopløsningen dernæst overtrækkes homogent på farmaceutiske excipienser.
DK200101258A 1999-02-26 2001-08-24 Stabiliseret oral farmaceutisk sammensætning indeholdende iodid og iodat samt fremgangsmåde til fremstilling heraf DK176595B1 (da)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US09/258,062 US6248335B1 (en) 1997-10-29 1999-02-26 Stabilized oral pharmaceutical composition containing iodide and iodate and method
US25806299 1999-02-26
PCT/US2000/004411 WO2000050046A1 (en) 1999-02-26 2000-02-22 Stabilized oral pharmaceutical composition containing iodide and iodate and method
US0004411 2000-02-22

Publications (2)

Publication Number Publication Date
DK200101258A true DK200101258A (da) 2001-10-26
DK176595B1 DK176595B1 (da) 2008-10-20

Family

ID=22978944

Family Applications (1)

Application Number Title Priority Date Filing Date
DK200101258A DK176595B1 (da) 1999-02-26 2001-08-24 Stabiliseret oral farmaceutisk sammensætning indeholdende iodid og iodat samt fremgangsmåde til fremstilling heraf

Country Status (19)

Country Link
US (1) US6248335B1 (da)
JP (1) JP2002537341A (da)
KR (1) KR100674324B1 (da)
CN (1) CN1344163A (da)
AT (1) AT413795B (da)
AU (1) AU778774B2 (da)
BR (1) BR0008509A (da)
CA (1) CA2366679C (da)
DE (1) DE10084290T1 (da)
DK (1) DK176595B1 (da)
ES (1) ES2226514B2 (da)
FI (1) FI20011703A (da)
GB (1) GB2364641B (da)
IL (1) IL144955A (da)
MX (1) MXPA01008550A (da)
NO (1) NO20014101L (da)
SE (1) SE0102843L (da)
WO (1) WO2000050046A1 (da)
ZA (1) ZA200106451B (da)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7147873B2 (en) * 2002-01-16 2006-12-12 3M Innovative Properties Company Antiseptic compositions and methods
US7198653B2 (en) 2003-07-31 2007-04-03 Delavau Llc Calcium carbonate granulation
CA2627154C (en) * 2004-12-24 2010-12-21 Council Of Scientific And Industrial Research An improved iodized salt and a process for its preparation
JP4885877B2 (ja) 2005-01-10 2012-02-29 セクレタリー・デパートメント・オブ・アトミック・エナジー 被影響体のインビボ環境から放射性セシウム（＊Ｃｓ）、放射性ストロンチウム（＊Ｓｒ）、および放射性ヨウ素（＊Ｉ）を同時除染する予防混合物
US8226964B2 (en) * 2006-09-07 2012-07-24 Biolargo Life Technologies, Inc. Systems and methods for cleaning liquid carriers related applications data
US7867510B2 (en) * 2006-09-07 2011-01-11 BioLargo Life Technologies, Inc Material having antimicrobial activity when wet
US20080063560A1 (en) * 2006-09-07 2008-03-13 Biolargo Life Technologies, Incorporated Ground treatment for reducing microbial content
US8021610B2 (en) * 2006-09-07 2011-09-20 Biolargo Life Technologies, Inc. Systems providing antimicrobial activity to an environment
US9414601B2 (en) * 2006-09-07 2016-08-16 Biolargo Life Technologies, Incorporated Material having antimicrobial activity when wet
US7943158B2 (en) * 2006-09-07 2011-05-17 BioLargo Life Technologies, Inc Absorbent systems providing antimicrobial activity
US9138414B1 (en) 2006-09-15 2015-09-22 Delavau Llc Calcium supplement having enhanced absorption
US8257749B2 (en) * 2007-02-08 2012-09-04 Biolargo Life Technologies, Incorporated Systems providing at least pesticidal activity
WO2009087647A1 (en) * 2008-01-07 2009-07-16 Council Of Scientific & Industrial Research A stabilized iodine-water concentrate formulation useful for protection against iodine deficiency disorders
US9622911B2 (en) 2010-09-30 2017-04-18 Cxl Ophthalmics, Llc Ophthalmic treatment device, system, and method of use
EP2830627B1 (en) 2012-03-29 2024-05-01 Epion Therapeutics, Inc. Ocular treatment solutions, delivery devices and delivery augmentation methods
US9566301B2 (en) 2012-03-29 2017-02-14 Cxl Ophthalmics, Llc Compositions and methods for treating or preventing diseases associated with oxidative stress
US9555111B2 (en) 2012-03-29 2017-01-31 Cxl Ophthalmics, Llc Ocular cross-linking system and method for sealing corneal wounds
WO2015080984A1 (en) 2013-11-27 2015-06-04 BioPharmX, Inc. Solid oral dosage form for breast symptoms
MX2016010328A (es) * 2014-02-10 2017-02-06 Hutchinson Fred Cancer Res Tratamiento con halogeno de ataque cardiaco y lesion isquemica.
US20170304359A1 (en) 2016-04-21 2017-10-26 BioPharmX, Inc. Oral iodine dosage form
MX2019000902A (es) 2016-07-21 2020-09-03 I2Pure Corp Desinfectantes topicos emolientes.
TW201813648A (zh) * 2016-09-16 2018-04-16 美商愛歐根有限責任公司 口服分子碘組合物與方法
WO2019237065A1 (en) * 2018-06-08 2019-12-12 Faraday Pharmaceuticals, Inc. Use of halogen compounds for the treatment and prevention of tissue injury and post-intensive care syndrome

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4486317A (en) * 1981-01-16 1984-12-04 E. I. Du Pont De Nemours And Company Stabilization of thickened aqueous fluids
RO85156B1 (ro) * 1983-05-27 1984-11-30 Institutul De Stiinte Biologice Comprimate-reactiv pentru determinarea alfa-anilazei si procedeu de obtinere a acestora
CN1036629C (zh) * 1991-03-16 1997-12-10 李克亮 动物促长剂
US5885592A (en) * 1997-10-29 1999-03-23 Symbollon Corporation Methods and pharmaceutical compositions for oral delivery of molecular iodine
WO1999034809A1 (fr) * 1998-01-06 1999-07-15 Fujisawa Pharmaceutical Co., Ltd. Preparations solides a base d'iodophore et procede de fabrication correspondant
US5985340A (en) * 1998-01-19 1999-11-16 Bolentica, Inc. Method for preparing iodine supplement for animal feeds

Also Published As

Publication number Publication date
CA2366679C (en) 2007-05-01
CN1344163A (zh) 2002-04-10
AU778774B2 (en) 2004-12-23
BR0008509A (pt) 2002-02-05
IL144955A0 (en) 2002-06-30
FI20011703A (fi) 2001-10-16
GB2364641B (en) 2004-06-30
GB0122808D0 (en) 2001-11-14
ATA90122000A (de) 2005-10-15
ES2226514A1 (es) 2005-03-16
WO2000050046A8 (en) 2003-11-27
SE0102843L (sv) 2001-10-26
IL144955A (en) 2006-12-31
ZA200106451B (en) 2002-08-06
CA2366679A1 (en) 2000-08-31
KR20010103014A (ko) 2001-11-17
SE0102843D0 (sv) 2001-08-27
US6248335B1 (en) 2001-06-19
WO2000050046A1 (en) 2000-08-31
MXPA01008550A (es) 2003-08-19
ES2226514B2 (es) 2007-02-16
NO20014101L (no) 2001-10-12
AU3371300A (en) 2000-09-14
DE10084290T1 (de) 2003-04-03
DK176595B1 (da) 2008-10-20
AT413795B (de) 2006-06-15
NO20014101D0 (no) 2001-08-23
FI20011703A0 (fi) 2001-08-24
KR100674324B1 (ko) 2007-01-24
GB2364641A (en) 2002-02-06
JP2002537341A (ja) 2002-11-05

Similar Documents

Publication Publication Date Title
DK200101258A (da) Stabiliseret oral farmaceutisk sammensætning indeholdende iodid og iodat samt fremgangsmåde til fremstilling heraf
JP4111536B2 (ja) 経口液体アレンドロナート組成物
JP3153577B2 (ja) 安定化固体化学組成物
EA002331B1 (ru) Фармацевтический препарат, содержащий клодронат в качестве активного ингредиента и агрегат микрокристаллической целлюлозы и диоксида кремния в качестве наполнителя
WO2008056926A1 (en) Complex formulation for preventing or treating osteoporosis which comprises solid dispersion of vitamin d or its derivative and bisphosphonate
HUT64961A (en) Inclusion complexes of clavulanic acid with hydrophylic and hydrophobic beta-cyclodextrin derivatives and method for producint them
ZA200203654B (en) Coating of tablet cores.
PT1436303E (pt) Sais de alendronato sob forma amorfa farmaceuticamente aceitaveis
EP2568959A2 (en) Formulations comprising a third generation cephalosporin and clavulanic acid
SU1009467A1 (ru) Средство дл растворени мочевых конкрементов
NZ334836A (en) Liquid alendronate formulations and their use in preventing bone resorption
AU745681B2 (en) A process for the preparation of solid oral dosage forms comprising alendronic acid
RU2001131898A (ru) Стабилизированный фармацевтический состав для перорального приема, содержащий йодит и йодат, и способ получения указанного состава
FI84697B (fi) Foerfarande foer framstaellning av en farmakologisk komposition med derivat av peroxidifosforsyra.
CH685600A5 (de) Peptid-Zubereitungen mit hypocalcämischer Wirkung.
US20240100084A1 (en) Use of functionalised chitosan in the treatment of inflammatory/fibrotic pathologies of the respiratory tract and hepatic pathologies
AP1820A (en) Use of specific dose of fondaparinux sodium for the treatment of ACS.
GB2395901A (en) Stabilised tablets containing iodide and iodate
PT98774A (pt) Processo para a preparacao de composicoes melhoradas de acido 5-(2,5-dimetilfenoxi)-2,2-dimetilpentanoico (gemfibrozil)
ITMI20001694A1 (it) Forme farmaceutiche contenenti clodronati per somministrazione intramuscolare ad elevata tollerabilita' locale.
HUT75639A (en) Aluminium containing pharmaceutical preparation with controlled release and a process for its production
JPH0840917A (ja) 向上した安全性側面を有する制酸薬調剤
JPH0430374B2 (da)

Legal Events

Date Code Title Description
PBP Patent lapsed

Ref document number: DK